Spots Global Cancer Trial Database for allogeneic hematopoietic cell transplant
Every month we try and update this database with for allogeneic hematopoietic cell transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | NCT05305040 | Adenovirus Infe... BK Virus Infect... Cytomegalovirus... Epstein-Barr Vi... Human Herpes Vi... JC Virus Infect... | Posoleucel (ALV... Placebo | - | AlloVir | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | NCT05305040 | Adenovirus Infe... BK Virus Infect... Cytomegalovirus... Epstein-Barr Vi... Human Herpes Vi... JC Virus Infect... | Posoleucel (ALV... Placebo | - | AlloVir | |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | NCT02259348 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Cyclophosphamid... Fludarabine G-CSF Interleukin-2 Melphalan Thiotepa Rituximab Natural killer ... T-cell depleted... CD45RA-depleted... | - 21 Years | St. Jude Children's Research Hospital | |
| Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | NCT04693637 | Adenovirus Infe... BK Virus Infect... Cytomegalovirus... Epstein-Barr Vi... Human Herpes Vi... JC Virus Infect... | Posoleucel (ALV... | 1 Year - | AlloVir | |
| Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients | NCT01333449 | Myelodysplastic... | Decitabine | 21 Years - 65 Years | Singapore General Hospital | |
| Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients | NCT01333449 | Myelodysplastic... | Decitabine | 21 Years - 65 Years | Singapore General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
